期刊文献+

复方血竭制剂与5-氨基水杨酸在溃疡性结肠炎临床维持缓解治疗中的疗效比较 被引量:8

Evaluation on Compound Dracorhodin Enema and Sulfasalazine in Maintenance Treatment for Clinical Remission of Ulcerative Colitis
暂未订购
导出
摘要 目的比较复方血竭灌肠液及口服5-氨基水杨酸(SASP)在溃疡性结肠炎(UC)临床维持缓解治疗中的疗效。方法以血竭、白芨为原料制备复方血竭灌肠液,对51例UC患者(血竭组)进行灌肠治疗6个月;SASP组给予SASP1.5g1次/d口服维持6个月,比较两组患者的复发率及治疗中的副作用。结果血竭组和SASP组疗效间差别无显著性意义(P>0.05);血竭组消化道反应、血液系统毒性、肝肾功能损害明显小于对照组(P<0.01)。结论复方血竭灌肠可用于高危患者及SASP治疗无效者的维持治疗方案。 Objective To compare the clinical efficacy of liquid compound dracorhodin enema and sulfasalazine in the maintenance treatment for remission of ulcerative colitis (UC). Methods Dracorhodin and bletilla striata were compounded into enema for the preparation of treatment, which was then administered to 51 patients of UC (dracorhodin group) for six months. Oral sulfasalazine (1.5 g per day) were meanwhile given to another group of patients (control group). The curative effects were evaluated by comparing the recurrence rates and the side-effects between the two groups. Results Difference in effect between the dracorhodin group and the control group was not significant (P〉0.05). Gastrointestinal reaction, blood system toxicity, and liver and kidney dysfunction were significantly less in the dracorhodin group than in the control group (P〈0.01).Conclusion Compound dracorhodin enema can be used for the treatment of the high-risk patients and of the patients who have no responses to sulfasalazine.
出处 《临床军医杂志》 CAS 2008年第4期540-541,共2页 Clinical Journal of Medical Officers
关键词 复方血竭制剂 溃疡性结肠炎 柳氮磺胺吡啶 维持缓解 compound dracorhodin enema ulcerative colitis sulfasalazine maintenance treatment
  • 相关文献

参考文献7

二级参考文献50

  • 1溃疡性结肠炎的诊断及疗效标准[J].中华消化杂志,1993,13(6):354-354. 被引量:1064
  • 2王雪明,吴凯,石玉玲,李娜.复方血竭灌肠剂的制备及临床应用[J].中国医院药学杂志,2005,25(3):281-281. 被引量:14
  • 3林一梅.加用中西药灌肠治疗溃疡性结肠炎36例疗效观察[J].中国全科医学,2005,8(17):1450-1450. 被引量:5
  • 4高应斗.血竭对血液流变性及血小板聚集功能的影响[J].山西医药杂志,1983,12(4):193-193.
  • 5[1]Moum B , Ekbom A , Vatn MH, et al. Clinical course duringthe 1st year after diagnosis in ulcerative colitis and Crohn' sdisease. Results of a large, prospective population - basedstudy in southeastern Norway, 1990 ~ 1993 [ J]. Scand Jgatroenterol, 1997,32:1 005.
  • 6[2]Langholz E, Munkholm P, Davidsen M, et al. Course ofulcerative colitis: analysis of changes in disease activity overyears[J]. Gastroenterology, 1994, 107:3.
  • 7[3]Feutren G, Mihatsch MJ . Risk factors for cyclosporine -induced nephropathy in patients with autoimmune diseases.International kidney biopsy registry of cyclosporine inautoimmune diseases[ J]. N Engl J Med, 1992,326:1 654.
  • 8[4]Lashner BA. gpidemiology of inflammatory bowel disease[J].Gatroenterol Clin North Am, 1995, 24:467.
  • 9[5]The Mesalamine Study Group. An oral preparation ofmesalamine as long - term maintenance therapy for ulcerativecolitis. A randomized, placebo - controlled trial [ J ]. AnnIntern Med , 1996, 124:204.
  • 10[6]Sutherland LR , Martin F. 5- Aminosalicylic acid enemas intreatment of distal ulcerative colitis and proctitis in Canada[J]. Dig Dis Sci, 1987, 32(suppl 12) :64S.

共引文献45

同被引文献158

引证文献8

二级引证文献142

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部